Remove tag people-health
article thumbnail

Biogen’s Alzheimer’s drug: What’s the price tag on hope?

World of DTC Marketing

Kesselheim, a professor of medicine at Harvard Medical School via the Washington Post , says “the worst thing for people with Alzheimer’s would be to put out a product that doesn’t work.” Still, Alzheimer’s is a nasty disease, and people are desperate for treatment even if it only provided a slim chance of partial recovery.

Drugs 187
article thumbnail

Grand Rounds February 2, 2024: Strategies for Improving Public Understanding of FDA and the Products It Regulates…Why Should We Care, and What Might We Do? (Susan C. Winckler, RPh, Esq)

Rethinking Clinical Trials

Food and Drug Administration, FDA, Misinformation, Communication, Health Information Key Points U.S. From January to September 2023, the Foundation conducted in-depth research and held 5 listening sessions to learn how people consume and understand health information. Observation 2: Information vacuums breed misunderstanding.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Grand Rounds September 22, 2023: Integrating Community Health Workers into Team-Based, Early Childhood Preventative Care (Tumaini Rucker Coker, MD, MBA)

Rethinking Clinical Trials

This may be the only interaction the family has with a healthcare professional, so if there are needs around behavior, health, social needs they will be addressed during these visits. Based on these findings, the research team initiated a larger PARENT trial that had 3 parent coaches at federally qualified health centers.

Trials 278
article thumbnail

Grand Rounds October 13, 2023: Incorporating Social Determinants of Health Into PCORnet (Keith Marsolo, PhD)

Rethinking Clinical Trials

Speaker Keith Marsolo, PhD Associate Professor Department of Population Health Sciences Duke University School of Medicine Slides Keywords PCORnet, Common Data Model, EHR, Social Determinants of Health Key Points There are many different definitions of social determinants of health.

article thumbnail

Grand Rounds October 20, 2023: A National Initiative to Eliminate Hepatitis C in the United States – Why This Matters to Clinical Trialists (Rachael L. Fleurence, PhD, MSc; Joshua M. Sharfstein, MD)

Rethinking Clinical Trials

Fleurence, PhD, MSc Senior Advisor National Institutes of Health Joshua M. There is now a cure for Hepatitis C, but many people are not able to access it. Many people do not know they have Hepatitis C (about 40% of patients).       Speakers Rachael L. Rates are the highest among 20-39-year-olds.

article thumbnail

Grand Rounds April 14, 2023: RECOVER in Action – Status of Clinical Trial Protocols (Kanecia Zimmerman, PhD, MD, MPH)

Rethinking Clinical Trials

We have people with experience with post-viral symptoms, treating ME/CFS, general COVID knowledge, biomarker experience, clinical trials, patient-reported outcomes, and more. – As people think about the health measures and outcomes, can you describe the process for how to understand and select those types of measures? .

article thumbnail

Grand Rounds February 9, 2024: Pragmatic Recruitment of Underrepresented Groups – Experience From the Diuretic Comparison Project (Cynthia Hau, MPH)

Rethinking Clinical Trials

Other key success factors were the creative thinking across the study team and the excellent study coordination and partnership within the health system. DCP learned that leveraging health systems for large-scale clinical trials is feasible. When people who are external to the VA view it as one homogeneous system, that is not the case.